For Immediate Release: February 10, 2015

Mary Kuramoto
513-579-9911 x2523

Medpace to Present on Risk-Based Monitoring at Upcoming SCOPE Meeting

Alexander Artyomenko, MD, Ph.D. to Provide Expert Insights

CINCINNATI, OH — (February 10, 2015) – Dr. Alexander Artyomenko, Global Director Late Phase at Medpace, a global CRO providing Phase I-IV core development services for drug, biologic, and device programs, will present at the SCOPE Summit for Clinical Operations Executives in Orlando, FL, February 24-26.

In Dr. Artyomenko’s presentation – Implementing a Risk-based Monitoring Approach from a CRO’s Perspective – he will address the need to coordinate and collaborate across functions within both the Sponsor and CRO organizations to breed success. Attendees will learn about taking holistic approach to building a customized adaptive monitoring program, its challenges, and perspectives for working with the medical, operational and technology teams. The Medpace sponsored luncheon takes place Wednesday, February 25, 2015 at 12:35pm in the monitoring track.

About Alexander Artyomenko, MD, Ph.D

Dr. Artyomenko is a cardiologist by training and has over 13 years of experience in Late Phase clinical research. His background encompasses both medical practice and clinical development, with a highly successful record in planning and executing Phase IIIb-IV studies. Dr. Artyomenko leads Medpace’s Late Phase services and has developed strategies for global trials in a variety of therapeutic areas for both pharmaceutical and medical device products. Dr. Artyomenko is an expert in global regulatory affairs concerning post-marketing and observational studies, expanded access/compassionate use programs, health economics and outcomes research, and registries. He is a professional member of the Institute of Clinical Research and an active member of the International Society for Pharmacoeconomics and Outcomes Research.



Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at: